Fluocinonide
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Fluocinonide: From Corticosteroid-Responsive Skin Conditions to Alopecia Mucinosa
One-Sentence Summary
Fluocinonide is a potent topical glucocorticoid, marketed in the US as a gel, cream, solution and ointment. The provided regulatory records list no approved indication text, so its original use comes from general drug-class knowledge. The TxGNN model predicts it may be effective for alopecia mucinosa, but there are currently 0 clinical trials and 0 publications for this indication. Among the other predicted hair-loss indications, only alopecia areata has any supporting items: 1 indirect trial and 1 case report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the provided license data (a potent topical corticosteroid, generally used for inflammatory skin conditions) |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 99.61% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (listed as ANDA generic applications) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on general drug-class knowledge, fluocinonide is a potent topical glucocorticoid with anti-inflammatory and immunosuppressive effects. This reasoning is not supported by any evidence provided here.
Alopecia mucinosa is an inflammatory follicular disorder, so an anti-inflammatory topical steroid could plausibly help. The very high score likely reflects that hair and follicle disorders cluster together in the knowledge graph, not a demonstrated drug effect. All seven predictions for this drug are hair-loss conditions, and their scores are nearly identical (99.5%–99.6%).
The predicted indications differ widely in how plausible they are:
- Alopecia areata (rank 3): immune-mediated inflammation around the hair follicle, so a mechanistic link is plausible. It is the only prediction with any supporting items, and they are indirect.
- Folliculitis decalvans (rank 4): a neutrophilic scarring alopecia, so inflammation control is conceivable, but no evidence was provided.
- Telogen effluvium (rank 2): generally a non-inflammatory, trigger-driven shedding disorder, so the rationale is weak.
- Hereditary hypotrichosis with recurrent skin vesicles (rank 5), alopecia antibody deficiency (rank 6), and alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome (rank 7): genetic or immunodeficiency syndromes with no evident link to glucocorticoid action.
Clinical Trial Evidence
Currently no related clinical trials registered for alopecia mucinosa.
For context, the only trial found across all predicted indications was attached to alopecia areata (rank 3). It studies a different disease and only gives indirect context:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04207931 | Phase 4 | Recruiting | 250 | Multicenter prospective study comparing treatment outcomes between groups in central centrifugal cicatricial alopecia (CCCA), a scarring alopecia rather than alopecia areata. The fluocinonide arm cannot be confirmed from the provided data (relevance grade C). |
Literature Evidence
Currently no related literature available for alopecia mucinosa.
For context, one publication was found under alopecia areata (rank 3):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15692503 | 2005 | Case report | J Am Acad Dermatol | Four cases of congenital alopecia areata followed for 3–5 years. Hair loss had long quiet periods, and treatments included minoxidil 2% and several topical agents. The provided abstract is truncated, so fluocinonide’s role cannot be confirmed. |
US Market Information
Of the 20 registered licenses, 5 main ones are listed below. Approved indication text was empty for all of them. Other dosage forms on the market include ointment.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA209030 | Fluocinonide | Gel | Padagis Israel Pharmaceuticals Ltd |
| ANDA210554 | Fluocinonide Cream | Cream | Preferred Pharmaceuticals Inc. |
| ANDA211111 | Fluocinonide | Cream | Asclemed USA, Inc. |
| ANDA210554 | Fluocinonide | Cream | A-S Medication Solutions |
| ANDA216389 | Fluocinonide | Solution | Quagen Pharmaceuticals LLC |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for alopecia mucinosa rests on the model score alone (L5), with no trials or literature. The best-supported hair-loss candidate, alopecia areata, has only one indirect trial and one case report (L4), so it is a research question rather than a candidate ready to advance.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data from DrugBank
- Approved indication text for the US licenses
- A targeted search for fluocinonide studies in alopecia areata and alopecia mucinosa
- Confirmation of whether fluocinonide is an intervention arm in NCT04207931
- Route compatibility assessment (currently pending)
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.